AMO Pharma Announces Completion of Treatment of Last Patient in Pivotal REACH-CDM Clinical Trial in Myotonic Dystrophy

/PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with...

Related Keywords

United Kingdom ,New Zealand ,Canada ,London ,City Of ,Australia ,Caitlin Oreilly ,Ibs Mahmood ,Nicholas Johnson ,Virginia Commonwealth University School Of Medicine ,Berry Company Public Relations ,Commission On Human Medicines ,Department Of Neurology ,Pharma Limited ,Drug Developers ,Myotonic Dystrophy Foundation On ,Chief Executive Officer ,Virginia Commonwealth University School ,Principal Investigator ,Myotonic Dystrophy Foundation ,Human Medicines ,Amo Pharma Limited ,